Last reviewed · How we verify

Atony of uterus — Treatment Landscape & Competitive Intelligence

Atony of uterus (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Atony of uterus, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Pabal CARBETOCIN Ferring Pharmaceuticals Ltd carbetocin Oxytocin receptor
Duratocin Duratocin Dongyu Wang Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V2 receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Dongyu Wang · 1 drug in Atony of uterus
  2. Ferring Pharmaceuticals Ltd · 1 drug in Atony of uterus

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Atony of uterus:

Cite this brief

Drug Landscape (2026). Atony of uterus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/atony-of-uterus. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing